308 results
8-K
EX-99.1
INVA
Innoviva Inc
13 May 24
Corporate Presentation May 2024
9:27am
platform supported by late - stage pipeline 3. Diversified, valuable portfolio of healthcare assets 4. Thoughtful, robust approach to long - term capital … Therapeutics Assets 12
Zoliflodacin, if approved, could address both near - term and long - term unmet needs as a single dose oral therapy Gonorrhea
8-K
EX-99.1
INVA
Innoviva Inc
8 May 24
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
4:44pm
million from XACDURO®, a 66% increase compared to $11.5 million for the first quarter of 2023.
Equity and long-term investments: First quarter 2024 … net change in fair values of equity and long-term investments of $22.0 million was primarily attributable to Armata Pharmaceuticals (“Armata”) share
8-K
EX-99.1
o2mzqonco 59nn4w9
29 Feb 24
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
4:15pm
8-K
EX-99.1
7fzjmednmysfosd
1 Nov 23
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
4:30pm
8-K
EX-99.1
zi2 8i5sh4brn
2 Aug 23
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
4:15pm
8-K
EX-99.1
wwuldesxsa8sv ggyd
24 May 23
Corporate Presentation May 2023
5:18pm
8-K
EX-99.1
87jv0wt4 tap
9 May 23
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent
5:21pm
8-K
EX-99.1
80yewjpbstm02dqp3
9 Nov 22
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:17pm
8-K/A
EX-99.1
7s5mur9ryhb 3566
28 Oct 22
Completion of Acquisition or Disposition of Assets
4:22pm
8-K
EX-99.1
libpd
14 Sep 22
Regulation FD Disclosure
5:22pm